Genetically Engineered HIV Vaccine INCREASED Risk of HIV Infection

A new study published in Lancet reveals that an experimental vaccine manufactured by Merck using a genetically modified adenovirus actually increased the risk of contracting HIV infection in recipients.

Titled, "Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study," researchers randomly assigned a total of 801 HIV-1 uninfected, sexually active adults aged 18—35 years from five sites in South Africa to receive either the vaccine (400) or a placebo (401). 216 (27%) received only one injection, 529 (66%) received only two injections, and 56 (7%) received three injections.